TrialNet studies for relatives
TrialNet is an international consortium of researchers who are working to find ways to prevent T1D. It is based in the US, with sites in Canada, Europe, Australia and New Zealand.
Professor Peter Colman and Dr John Wentworth head the Australasian TrialNet Center and oversee a number of prevention studies.
TrialNet Pathway to Prevention
This study is looking for:
Relatives of people with T1D aged between 1 and 45 years
About this study
People with a family history of T1D are 10 to 15 times more likely to develop it than people without a family history. This study offers a screening blood test for autoantibodies to detemine whether relatives are at high-risk.
Relatives who are considered high-risk of developing T1D are offered participation in follow-on studies.
The TrialNet Pathway to Prevention study aims to increase our understanding of how T1D develops and to identify high-risk people suitable for prevention trials.
The screening blood test can be performed at our study centers located in Brisbane, Sydney, Newcastle, Melbourne, Adelaide and Perth, or in the community through a local pathology collection centre.
Over 95% of people test negative and can be reassured that their risk of developing T1D is low. Yearly re-screening is offered to children because autoantibodies can develop despite an initial negative screen in this group.
To be eligible for the TrialNet Pathway to Prevention Study you must be over 1 year of age and either under the age of 45 with a first degree relative with T1D or under the age of 20 with a second degree relative (eg cousin, uncle, aunt or grandparent) with T1D.
For more information about this study